Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 287-295
Closed Access | Times Cited: 153

Showing 1-25 of 153 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 254
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Arun J. Sanyal, Pierre Bédossa, Mandy Fraessdorf, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 4, pp. 311-319
Open Access | Times Cited: 113
Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
Yueqiong Ni, Lingling Qian, Sara Leal Siliceo, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1530-1547.e8
Open Access | Times Cited: 69
Global burden of metabolic diseases, 1990–2021
Huai Zhang, Xiaodong Zhou, Michael D. Shapiro, et al.
Metabolism (2024) Vol. 160, pp. 155999-155999
Closed Access | Times Cited: 56
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 51
Natural history of metabolic dysfunction-associated steatotic liver disease
Vasileios Lekakis, George Papatheodoridis
European Journal of Internal Medicine (2023) Vol. 122, pp. 3-10
Closed Access | Times Cited: 48
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 26
Steatotic liver disease
Mads Israelsen, Sven Francque, Emmanuel Tsochatzis, et al.
The Lancet (2024) Vol. 404, Iss. 10464, pp. 1761-1778
Closed Access | Times Cited: 24
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 19
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2024
Anne F. Peery, Caitlin C. Murphy, Chelsea Anderson, et al.
Gastroenterology (2025)
Closed Access | Times Cited: 1
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 335-351
Open Access | Times Cited: 32
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Matheus Souza, Ivanna Diaz, Ilaria Barchetta, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 6-14
Open Access | Times Cited: 27
Natural products in non-alcoholic fatty liver disease (NAFLD): Novel lead discovery for drug development
Lu Wang, Yonghuan Yan, Linfang Wu, et al.
Pharmacological Research (2023) Vol. 196, pp. 106925-106925
Open Access | Times Cited: 24
Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
Florian Plaza Oñate, Célia Chamignon, Sebastian D. Burz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12232-12232
Open Access | Times Cited: 22
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Amedeo Lonardo, Stefano Ballestri, Alessandro Mantovani, et al.
Metabolites (2024) Vol. 14, Iss. 1, pp. 40-40
Open Access | Times Cited: 12
The global burden of fatty liver disease: the major impact of China
Tian-Wen Lou, Rui‐Xu Yang, Jian‐Gao Fan
HepatoBiliary Surgery and Nutrition (2024) Vol. 13, Iss. 1, pp. 119-123
Open Access | Times Cited: 12
Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
Haider Ghazanfar, Nismat Javed, Abeer Qasim, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1214-1214
Open Access | Times Cited: 12
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
Huai Zhang, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1178-1201
Closed Access | Times Cited: 10
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective
Jialan Wang, Suwen Jiang, Airong Hu, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27325-e27325
Open Access | Times Cited: 9
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals
Matheus Souza, Ivanna Diaz, Lubna Al‐Sharif
Hepatology International (2024) Vol. 18, Iss. 5, pp. 1396-1415
Closed Access | Times Cited: 9
Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population
Haoxuan Zou, Xiaopu Ma, Wen Pan, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 8
Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study
Matina Kouvari, Laura Valenzuela‐Vallejo, Evangelos Axarloglou, et al.
Liver International (2024) Vol. 44, Iss. 3, pp. 848-864
Open Access | Times Cited: 7
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 7
MASLD treatment—a shift in the paradigm is imminent
Mariana Verdelho Machado
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 16
Trimethylamine N-oxide, choline and its metabolites are associated with the risk of non-alcoholic fatty liver disease
Rong Ma, Guang-Ying Shi, Yanfang Li, et al.
British Journal Of Nutrition (2024) Vol. 131, Iss. 11, pp. 1915-1923
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top